Based on the above observations, we hypothesized that a higher level of LNK expression will suppress the interferon pathway and confer a selective survival advantage to melanoma cells; therefore, those patients who have higher levels of LNK expressed in their tumor cells will be less likely to respond to PD-1 antibody therapy. This evidence concerns the gene SH2B3 and neoplasm.